New data supporting modified RECIST (mRECIST) for hepatocellular carcinoma

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1312-1314

  Lencioni, Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESEARCH; CANCER SIZE; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; HUMAN; LIVER CELL CARCINOMA; MEDICAL SOCIETY; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; MOLECULARLY TARGETED THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TREATMENT RESPONSE;

CARCINOMA, HEPATOCELLULAR; FEMALE; GUIDELINES AS TOPIC; HUMANS; LIVER NEOPLASMS; MALE; SURVIVAL ANALYSIS;

EID: 84875127097     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3796     Document Type: Article

References (12)

1. Kim BK, Kim SU, Kim MJ, Kim KA, Kim DY, Park JY, et al. Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 2013;19:1503-11.
2. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
3. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011;55:1309-16.
4. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012;262:708-18.
5. Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, et al. mRECIST and EASL responses at early time point by contrastenhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2012 Dec 5. [Epub ahead of print].
6. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
7. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al.Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
8. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010;28:3994-4005.
9. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118:147-56.
10. Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, et al. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012;83:192-200.
11. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
12. Verslype C, Rosmorduc O, Rougier P ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii41-8.